INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. OBJECTIVE: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. METHODS: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. RESULTS: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15-41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65-0.88); in those aged ≤ 38 years (0.64; 0.54-0.76); in those with disease duration ≤ 7 years (0.63; 0.53-0.76); in those with EDSS score < 4 (0.75; 0.64-0.88), < 6 (0.80; 0.70-0.91), and ≥ 6 (0.52; 0.31-0.86); and in patients with pre-baseline relapses (0.74; 0.64-0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10-1.66); those aged > 38 years (1.34; 1.04-1.73); those with disease duration > 7 years (1.33; 1.01-1.74); those with EDSS score < 6 (1.21; 1.01-1.46) and ≥ 6 (1.93; 1.11-3.34); and patients with no new MRI lesion (1.73; 1.19-2.51). CONCLUSIONS: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.

Aarhus University Hospital Neurology PPJ Boulevard 8200 Aarhus N Denmark

Aix Marseille Univ APHM Hôpital de la Timone Pôle de Neurosciences Cliniques Service de Neurologie 13005 Marseille France

Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Italy

Central Clinical School Monash University Melbourne Australia

Centre de Ressources et de Compétences SEP Paris France

Centre des Neurosciences de Lyon Observatoire Français de la Sclérose en Plaques INSERM 1028 et CNRS UMR5292 69003 Lyon France

CHU de Besançon Service de Neurologie 25 030 Besançon France

CHU de Nantes Service de Neurologie and CIC015 INSERM 44093 Nantes France

CHU Lille CRCSEP Lille Univ Lille U1172 59000 Lille France

CHU Pontchaillou CIC1414 INSERM 35000 Rennes France

CHUM MS Center and Universite de Montreal Montreal Canada

CISSS Chaudière Appalache Levis Canada

College of Medicine and Public Health Flinders University Adelaide Australia

CORe Department of Medicine University of Melbourne L4 East Grattan St Melbourne VIC 3050 Australia

CRC SEP and Department of Neurology CHU de Tours Hôpital Bretonneau 37000 Tours France

CRCSEP Nice UR2CA Université Nice Cote d'Azur Hopital Pasteur2 06002 Nice France

CRTI Inserm U1064 44000 Nantes France

CSSS Saint Jérôme Saint Jerome Canada

Département de neurologie Hôpital Pitié Salpêtrière APHP Paris France

Department of Basic Medical Sciences Neuroscience and Sense Organs University of Bari Bari Italy

Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark

Department of Emergency and General Medicine Parma University Hospital Parma Italy

Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia Catania Italy

Department of Medicine and Surgery University of Parma Parma Italy

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Department of Neurology and Clinical Investigation Center CHU de Strasbourg CIC 1434 INSERM 1434 67000 Strasbourg France

Department of Neurology AP HP Saint Antoine Hospital 75000 Paris France

Department of Neurology APHP Hôpital Henri Mondor 94000 Créteil France

Department of Neurology Box Hill Hospital Monash University Melbourne Australia

Department of Neurology Centre Hospitalier de Versailles 78150 Le Chesnay France

Department of Neurology CH de Pontoise Hôpital René Dubos 95300 Pontoise France

Department of Neurology CHU Bicêtre 94275 Le Kremlin Bicêtre France

Department of Neurology CHU Clermont Ferrand 63000 Clermont Ferrand France

Department of Neurology CHU d'Amiens 80000 Amiens France

Department of Neurology CHU de Bordeaux CIC Bordeaux CIC1401 33000 Bordeaux France

Department of Neurology CHU de Caen MS Expert Centre Normandy University avenue de la Côte de Nacre 14033 Caen France

Department of Neurology CHU de Dijon EA4184 21000 Dijon France

Department of Neurology CHU de la Martinique 97200 Fort de France France

Department of Neurology CHU de Limoges Hôpital Dupuytren 87000 Limoges France

Department of Neurology CHU de Rouen 76000 Rouen France

Department of Neurology CHU de Saint Étienne Hôpital Nord 42000 Saint Étienne France

Department of Neurology CHU de Toulouse Hôpital Pierre Paul Riquet CRC SEP 31059 Toulouse Cedex 9 France

Department of Neurology CHU Grenoble Alpes La Tronche 38700 Grenoble France

Department of Neurology CHU La Milétrie Hôpital Jean Bernard 86000 Poitiers France

Department of Neurology Copenhagen University Hospital Herlev Herlev Denmark

Department of Neurology Danish Multiple Sclerosis Centre Copenhagen University Hospital Rigshospitalet in Glostrup 2600 Glostrup Denmark

Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Neurology Fondation Rotschild 75000 Paris France

Department of Neurology Hôpital de Poissy 78300 Poissy France

Department of Neurology Hôpital Pierre Delafontaine Centre Hospitalier de Saint Denis 93200 Saint Denis France

Department of Neurology Hôpital Sud Francilien 91160 Corbeil Essonnes France

Department of Neurology John Hunter Hospital Hunter New England Health Newcastle Australia

Department of Neurology Nancy University Hospital Nancy France

Department of Neurology Nimes University Hospital 30029 Nimes Cedex 9 France

Department of Neurology Rigshospitalet Glostrup Copenhagen Denmark

Department of Neurology The Alfred Hospital Melbourne Australia

Department of Neurology The Danish Multiple Sclerosis Center University of Copenhagen Rigshospitalet Copenhagen Denmark

Department of Neurology University Hospital of Northern Sealand Helsingør Denmark

Department of Neuroscience Azienda Ospedaliera Universitaria Modena Italy

Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy

Department of Neuroscience Monash University Melbourne Australia

Dipartimento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italia

Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait

Dokuz Eylul University Konak Izmir Turkey

EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis State Approved Foundation 69677 Bron France

Haydarpasa Numune Training and Research Hospital Istanbul Turkey

Hospital Universitario Virgen Macarena Seville Spain

INSERM U1215 Neurocentre Magendie 33000 Bordeaux France

Institut de Génomique Fonctionnelle UMR5203 INSERM 1191 Univ Montpellier 34094 Montpellier Cedex 5 France

Institute of Clinical Medicine University of Copenhagen Copenhagen Denmark

IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy

KTU Medical Faculty Farabi Hospital Trabzon Turkey

Medical Faculty 19 Mayis University Samsun Turkey

MS Centre Department of Neurology Royal Melbourne Hospital Melbourne Australia

MS Unit CHU de Montpellier 34295 Montpellier Cedex 5 France

Multiple Sclerosis Center University of Catania Catania Italy

Multiple Sclerosis Unit Department of Neurology Aalborg University Hospital Aalborg Denmark

Nehme and Therese Tohme Multiple Sclerosis Center American University of Beirut Medical Center Beirut Lebanon

Neuro Rive Sud Greenfield Park Quebec Canada

Neurocentre Magendie Université de Bordeaux 33000 Bordeaux France

Neurology Unit Garibaldi Hospital Catania Italy

Neurophysiology Department Westmead Hospital Sydney Australia

Observatoire Français de la Sclérose en Plaques Centre de Recherche en Neurosciences de Lyon INSERM 1028 et CNRS UMR 5292 69003 Lyon France

Rehabilitation and MS Centre Overpelt and Hasselt University Hasselt Belgium

Rennes University EHESP REPERES EA 7449 Rennes France

Royal Brisbane and Women's Hospital Brisbane Australia

School of Medicine and Public Health University Newcastle Newcastle Australia

Service de neurologie sclérose en plaques pathologies de la myéline et neuro inflammation Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon Bron Lyon France

Sorbonne Universités UPMC Paris 06 Brain and Spine Institute ICM Hôpital de la Pitié Salpêtrière Inserm UMR S 1127 CNRS UMR 7225 Paris France

The Danish Multiple Sclerosis Registry Department of Neurology University of Copenhagen Rigshospitalet Copenhagen Denmark

Univ Rennes CHU Rennes Inserm CIC 1414 Rennes France

Université Claude Bernard Lyon 1 Faculté de médecine Lyon Est F 69000 Lyon France

Université Clermont Auvergne Inserm Neuro Dol 63000 Clermont Ferrand France

Université de Lorraine APEMAC 54000 Nancy France

Université de Lyon Université Claude Bernard Lyon 1 F 69000 Lyon France

University of Montpellier 34000 Montpellier France

University of Queensland Brisbane Australia

000      

00000naa a2200000 a 4500

001      

bmc22011974

003      

CZ-PrNML

005      

20220506125840.0

007      

ta

008      

220425s2021 nz f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s40263-021-00860-7 $2 doi

035    __

$a (PubMed)34536228

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a nz

100    1_

$a Sharmin, Sifat $u CORe, Department of Medicine, University of Melbourne, L4 East, Grattan St, Melbourne, VIC, 3050, Australia

245    10

$a Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts / $c S. Sharmin, M. Lefort, JB. Andersen, E. Leray, D. Horakova, EK. Havrdova, R. Alroughani, G. Izquierdo, S. Ozakbas, F. Patti, M. Onofrj, A. Lugaresi, M. Terzi, P. Grammond, F. Grand'Maison, B. Yamout, A. Prat, M. Girard, P. Duquette, C. Boz, M. Trojano, P. McCombe, M. Slee, J. Lechner-Scott, R. Turkoglu, P. Sola, D. Ferraro, F. Granella, J. Prevost, D. Maimone, O. Skibina, K. Buzzard, A. Van der Walt, B. Van Wijmeersch, T. Csepany, D. Spitaleri, S. Vucic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De Sèze, E. Maillart, H. Zephir, P. Labauge, G. Defer, C. Lebrun-Frénay, T. Moreau, E. Berger, P. Clavelou, J. Pelletier, B. Stankoff, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Wahab, JP. Camdessanché, A. Maurousset, I. Patry, K. Hankiewicz, C. Pottier, N. Maubeuge, C. Labeyrie, C. Nifle, D. Laplaud, N. Koch-Henriksen, FT. Sellebjerg, PS. Soerensen, CC. Pfleger, PV. Rasmussen, MB. Jensen, JL. Frederiksen, S. Bramow, HK. Mathiesen, KI. Schreiber, M. Magyari, S. Vukusic, H. Butzkueven, T. Kalincik, Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators

520    9_

$a INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. OBJECTIVE: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. METHODS: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. RESULTS: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15-41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65-0.88); in those aged ≤ 38 years (0.64; 0.54-0.76); in those with disease duration ≤ 7 years (0.63; 0.53-0.76); in those with EDSS score < 4 (0.75; 0.64-0.88), < 6 (0.80; 0.70-0.91), and ≥ 6 (0.52; 0.31-0.86); and in patients with pre-baseline relapses (0.74; 0.64-0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10-1.66); those aged > 38 years (1.34; 1.04-1.73); those with disease duration > 7 years (1.33; 1.01-1.74); those with EDSS score < 6 (1.21; 1.01-1.46) and ≥ 6 (1.93; 1.11-3.34); and patients with no new MRI lesion (1.73; 1.19-2.51). CONCLUSIONS: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.

650    _2

$a dospělí $7 D000328

650    _2

$a kohortové studie $7 D015331

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a fingolimod hydrochlorid $x terapeutické užití $7 D000068876

650    _2

$a následné studie $7 D005500

650    _2

$a lidé $7 D006801

650    _2

$a imunologické faktory $x terapeutické užití $7 D007155

650    _2

$a imunosupresiva $x terapeutické užití $7 D007166

650    12

$a internacionalita $7 D038622

650    _2

$a longitudinální studie $7 D008137

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a relabující-remitující roztroušená skleróza $x diagnóza $x farmakoterapie $x epidemiologie $7 D020529

650    _2

$a natalizumab $x terapeutické užití $7 D000069442

650    12

$a registrace $7 D012042

650    _2

$a sekundární prevence $7 D055502

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a pozorovací studie $7 D064888

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Lefort, Mathilde $u Rennes University, EHESP, REPERES, EA, 7449, Rennes, France $u Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France

700    1_

$a Andersen, Johanna Balslev $u The Danish Multiple Sclerosis Registry, Department of Neurology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark

700    1_

$a Leray, Emmanuelle $u Rennes University, EHESP, REPERES, EA, 7449, Rennes, France $u Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France

700    1_

$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

700    1_

$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

700    1_

$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait

700    1_

$a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Seville, Spain

700    1_

$a Ozakbas, Serkan $u Dokuz Eylul University, Konak, Izmir, Turkey

700    1_

$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy $u Multiple Sclerosis Center, University of Catania, Catania, Italy

700    1_

$a Onofrj, Marco $u Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy

700    1_

$a Lugaresi, Alessandra $u IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy $u Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italia

700    1_

$a Terzi, Murat $u Medical Faculty, 19 Mayis University, Samsun, Turkey

700    1_

$a Grammond, Pierre $u CISSS Chaudière-Appalache, Levis, Canada

700    1_

$a Grand'Maison, Francois $u Neuro Rive-Sud, Greenfield Park, Quebec, Canada

700    1_

$a Yamout, Bassem $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon

700    1_

$a Prat, Alexandre $u CHUM MS Center and Universite de Montreal, Montreal, Canada

700    1_

$a Girard, Marc $u CHUM MS Center and Universite de Montreal, Montreal, Canada

700    1_

$a Duquette, Pierre $u CHUM MS Center and Universite de Montreal, Montreal, Canada

700    1_

$a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey

700    1_

$a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy

700    1_

$a McCombe, Pamela $u University of Queensland, Brisbane, Australia $u Royal Brisbane and Women's Hospital, Brisbane, Australia

700    1_

$a Slee, Mark $u College of Medicine and Public Health, Flinders University, Adelaide, Australia

700    1_

$a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University Newcastle, Newcastle, Australia $u Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia

700    1_

$a Turkoglu, Recai $u Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey

700    1_

$a Sola, Patrizia $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy

700    1_

$a Ferraro, Diana $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy

700    1_

$a Granella, Franco $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Department of Emergency and General Medicine, Parma University Hospital, Parma, Italy

700    1_

$a Prevost, Julie $u CSSS Saint-Jérôme, Saint-Jerome, Canada

700    1_

$a Maimone, Davide $u Neurology Unit, Garibaldi Hospital, Catania, Italy

700    1_

$a Skibina, Olga $u Department of Neuroscience, Monash University, Melbourne, Australia $u Department of Neurology, The Alfred Hospital, Melbourne, Australia

700    1_

$a Buzzard, Katherine $u Department of Neurology, The Alfred Hospital, Melbourne, Australia $u Central Clinical School, Monash University, Melbourne, Australia

700    1_

$a Van der Walt, Anneke $u Department of Neurology, The Alfred Hospital, Melbourne, Australia $u Central Clinical School, Monash University, Melbourne, Australia

700    1_

$a Van Wijmeersch, Bart $u Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium

700    1_

$a Csepany, Tunde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

700    1_

$a Spitaleri, Daniele $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy

700    1_

$a Vucic, Steve $u Neurophysiology Department, Westmead Hospital, Sydney, Australia

700    1_

$a Casey, Romain $u Université de Lyon, Université, Claude Bernard Lyon 1, F-69000, Lyon, France $u Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, Lyon, France $u Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, 69003, Lyon, France $u EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis, State-Approved Foundation, 69677, Bron, France

700    1_

$a Debouverie, Marc $u Department of Neurology, Nancy University Hospital, Nancy, France $u Université de Lorraine, APEMAC, 54000, Nancy, France

700    1_

$a Edan, Gilles $u CHU Pontchaillou, CIC1414 INSERM, 35000, Rennes, France

700    1_

$a Ciron, Jonathan $u Department of Neurology, CHU de Toulouse, Hôpital Pierre-Paul Riquet, CRC-SEP, 31059, Toulouse Cedex 9, France

700    1_

$a Ruet, Aurélie $u Neurocentre Magendie, Université de Bordeaux, 33000, Bordeaux, France $u INSERM U1215, Neurocentre Magendie, 33000, Bordeaux, France $u Department of Neurology, CHU de Bordeaux, CIC Bordeaux CIC1401, 33000, Bordeaux, France

700    1_

$a De Sèze, Jérôme $u Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, CIC 1434, INSERM 1434, 67000, Strasbourg, France

700    1_

$a Maillart, Elisabeth $u Département de neurologie, Hôpital Pitié-Salpêtrière, APHP, Paris, France $u Centre de Ressources et de Compétences SEP, Paris, France

700    1_

$a Zephir, Hélène $u CHU Lille, CRCSEP Lille, Univ Lille, U1172, 59000, Lille, France

700    1_

$a Labauge, Pierre $u MS Unit, CHU de Montpellier, 34295, Montpellier Cedex 5, France $u University of Montpellier (MUSE), 34000, Montpellier, France

700    1_

$a Defer, Gilles $u Department of Neurology, CHU de Caen, MS Expert Centre, Normandy University, avenue de la Côte-de-Nacre, 14033, Caen, France

700    1_

$a Lebrun-Frénay, Christine $u CRCSEP Nice, UR2CA, Université Nice Cote d'Azur, Hopital Pasteur2, 06002, Nice, France

700    1_

$a Moreau, Thibault $u Department of Neurology, CHU de Dijon, EA4184, 21000, Dijon, France

700    1_

$a Berger, Eric $u CHU de Besançon, Service de Neurologie 25 030, Besançon, France

700    1_

$a Clavelou, Pierre $u Department of Neurology, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France $u Université Clermont Auvergne, Inserm, Neuro-Dol, 63000, Clermont-Ferrand, France

700    1_

$a Pelletier, Jean $u Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, 13005, Marseille, France

700    1_

$a Stankoff, Bruno $u Sorbonne Universités, UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de la Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, Paris, France $u Department of Neurology, AP-HP, Saint-Antoine Hospital, 75000, Paris, France

700    1_

$a Gout, Olivier $u Department of Neurology, Fondation Rotschild, 75000, Paris, France

700    1_

$a Thouvenot, Eric $u Department of Neurology, Nimes University Hospital, 30029, Nimes Cedex 9, France $u Institut de Génomique Fonctionnelle, UMR5203, INSERM 1191, Univ. Montpellier, 34094, Montpellier Cedex 5, France

700    1_

$a Heinzlef, Olivier $u Department of Neurology, Hôpital de Poissy, 78300, Poissy, France

700    1_

$a Al-Khedr, Abullatif $u Department of Neurology, CHU d'Amiens, 80000, Amiens, France

700    1_

$a Bourre, Bertrand $u Department of Neurology, CHU de Rouen, 76000, Rouen, France

700    1_

$a Casez, Olivier $u Department of Neurology, CHU Grenoble Alpes, La Tronche, 38700, Grenoble, France

700    1_

$a Cabre, Philippe $u Department of Neurology, CHU de la Martinique, 97200, Fort-de-France, France

700    1_

$a Montcuquet, Alexis $u Department of Neurology, CHU de Limoges, Hôpital Dupuytren, 87000, Limoges, France

700    1_

$a Wahab, Abir $u Department of Neurology, APHP, Hôpital Henri Mondor, 94000, Créteil, France

700    1_

$a Camdessanché, Jean-Philippe $u Department of Neurology, CHU de Saint-Étienne, Hôpital Nord, 42000, Saint-Étienne, France

700    1_

$a Maurousset, Aude $u CRC SEP and Department of Neurology, CHU de Tours, Hôpital Bretonneau, 37000, Tours, France

700    1_

$a Patry, Ivania $u Department of Neurology, Hôpital Sud Francilien, 91160, Corbeil Essonnes, France

700    1_

$a Hankiewicz, Karolina $u Department of Neurology, Hôpital Pierre Delafontaine, Centre Hospitalier de Saint-Denis, 93200, Saint-Denis, France

700    1_

$a Pottier, Corinne $u Department of Neurology, CH de Pontoise, Hôpital René Dubos, 95300, Pontoise, France

700    1_

$a Maubeuge, Nicolas $u Department of Neurology, CHU La Milétrie, Hôpital Jean Bernard, 86000, Poitiers, France

700    1_

$a Labeyrie, Céline $u Department of Neurology, CHU Bicêtre, 94275, Le Kremlin Bicêtre, France

700    1_

$a Nifle, Chantal $u Department of Neurology, Centre Hospitalier de Versailles, 78150, Le Chesnay, France

700    1_

$a Laplaud, David $u CHU de Nantes, Service de Neurologie & CIC015 INSERM, 44093, Nantes, France $u CRTI-Inserm U1064, 44000, Nantes, France

700    1_

$a Koch-Henriksen, Niels $u Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

700    1_

$a Sellebjerg, Finn Thorup $u Department of Neurology, The Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark

700    1_

$a Soerensen, Per Soelberg $u Department of Neurology, The Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark

700    1_

$a Pfleger, Claudia Christina $u Multiple Sclerosis Unit, Department of Neurology, Aalborg University Hospital, Aalborg, Denmark

700    1_

$a Rasmussen, Peter Vestergaard $u Aarhus University Hospital, Neurology, PPJ Boulevard, 8200, Aarhus N, Denmark

700    1_

$a Jensen, Michael Broksgaard $u Department of Neurology, University Hospital of Northern Sealand, Helsingør, Denmark

700    1_

$a Frederiksen, Jette Lautrup $u Department of Neurology, Rigshospitalet Glostrup, Copenhagen, Denmark $u Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

700    1_

$a Bramow, Stephan $u Department of Neurology, Danish Multiple Sclerosis Centre, Copenhagen University Hospital, Rigshospitalet in Glostrup, 2600, Glostrup, Denmark

700    1_

$a Mathiesen, Henrik Kahr $u Department of Neurology, Copenhagen University Hospital Herlev, Herlev, Denmark

700    1_

$a Schreiber, Karen Ingrid $u Department of Neurology, The Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark

700    1_

$a Magyari, Melinda $u The Danish Multiple Sclerosis Registry, Department of Neurology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark $u Department of Neurology, The Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark

700    1_

$a Vukusic, Sandra $u Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, Lyon, France $u Centre des Neurosciences de Lyon, Observatoire Français de la Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, 69003, Lyon, France $u Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, F-69000, Lyon, France

700    1_

$a Butzkueven, Helmut $u Department of Neurology, The Alfred Hospital, Melbourne, Australia $u Central Clinical School, Monash University, Melbourne, Australia $u Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia

700    1_

$a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, L4 East, Grattan St, Melbourne, VIC, 3050, Australia. tomas.kalincik@unimelb.edu.au $u MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. tomas.kalincik@unimelb.edu.au $1 https://orcid.org/0000000337781376

710    2_

$a Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators

773    0_

$w MED00001186 $t CNS drugs $x 1179-1934 $g Roč. 35, č. 11 (2021), s. 1217-1232

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34536228 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506125832 $b ABA008

999    __

$a ok $b bmc $g 1789521 $s 1163175

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 35 $c 11 $d 1217-1232 $e 20210918 $i 1179-1934 $m CNS drugs $n CNS Drugs $x MED00001186

LZP    __

$a Pubmed-20220425